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Abstract
Background: There is limited information about the medium to long-term health-related quality of life (QOL) in
thyroid cancer patients after initial therapy and the existing studies suffer from limitations. The aim of the study
was to assess the determinants of medium-term QOL after the initial therapy.
Methods: Following a total thyroidectomy, 88 thyroid cancer patients received either rhTSH or hypothyroid-
assisted radioiodine ablation (RRA) using 3.7 GBq (100 mCi) of radioiodine. QOL evaluation of the patients using
the validated Functional Assessment of Chronic Illness & Therapy (FACIT) was performed at the time of inclusion
(t0) and later at the 9-month post-RRA (t1).
Results: 83 patients were eligible for the final evaluation. Medium-term FACIT scores were not statistically different
between t0 and t1 patients. All but one domain of the QOL score was similar between t0 and t1. Using a
multivariate analysis, only age and immediate postoperative QOL scores were found to be determinants of the
overall medium term 9-month QOL scores. Analysis showed that ‘high QOL levels’ (baseline and 9-month) and ‘no
depression’, ‘low anxiety levels’, were associated with ‘<45yrs’, ‘men’, ‘partner’, and ‘rhTSH stimulation’.
Conclusions: The use of radioiodine ablation does not seem to affect the medium term QOL scores of patients.
Medium-term QOL is mainly determined by pre-ablation QOL. The assessment of baseline QOL might be
interesting to evaluate in order to adapt the treatment protocols, the preventive strategies, and medical
information to patients for potentially improving their outcomes.
Background
Most well-differentiated thyroid cancers (WDTC) are
treated with a total thyroidectomy followed by selective
use of radioiodine for remnant ablation (RRA) [1-6].
Survival rates are excellent but poor quality of life
(QOL) outcomes have been reported in thyroid cancer
patients. The use of recombinant TSH (rhTSH) for RRA
improves QOL during the peri-ablation period but its
impact beyond this period remains to be determined in
a model including other factors that contribute to influ-
ence QOL [7,8]. There is limited information about the
medium to long-term quality of life (QOL) and the
existing studies suffer from limitations including a
cross-sectional design [9-14], a small sample size
[15,16], the small number of QOL domains assessed
[10,16] and the absence of baseline QOL data.
In our previous report, we found that the 9-month
QOL (medium term QOL) did not differ according to
the TSH stimulation method (rhTSH or hypothyroid-
assisted RAA) but we did not take into account the
QOL potential confounding variables including the base-
line QOL status of patients [8].
The aim of the present prospective study was to iden-
tify the determinants of the medium term QOL after
complete initial therapy.
Methods
Study design and data collection
This is a longitudinal study. Newly diagnosed well-dif-
ferentiated papillary or follicular thyroid cancer patients
were included. Subjects were staged pT1-T3, N0-Nx-N1,
M0 (if <5 nodes and without extracapsular spread), had
total thyroidectomy and underwent RRA (either rhTSH
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dine). The patients were assessed at the time of study
inclusion (t0) and at the 9 month-post-RRA follow-up
control (t1). The following data were collected: socio-
demographic parameters, pTNM stage, clinical data,
anxiety (Spielberger trait anxiety inventory) [17,18],
depression (self-administered Beck Depression Inven-
tory, BDI) [19], and QOL (functional assessment of
chronic illness therapy, FACIT) scores [20-22]. This
study was integrated in a prospective randomized study
previously described in detail
8,i nw h i c ht h ep r i m a r y
objective was to compare the impact and the efficacy of
two TSH stimulation procedures. The aim of this pre-
sent report was a secondary objective of the original
protocol.
Instruments to assess anxiety, depression and quality of
life
1. The level of anxiety was assessed with the state
scale of the Spielberger trait anxiety inventory (20
items, scale range 20-80, higher scores correspond-
ing to higher levels of anxiety).
2. The BDI score range is 0-39, with higher scores
indicating worsening depression (score 0-<4: no
depression, 4-<8: mild depression, 8-<30: moderate
depression; score >30: severe depression).
3. The QOL was assessed using the functional
assessment of chronic illness therapy. Functional
assessment of chronic illness therapy (FACIT) is a
well validated and widely used tool for evaluation of
QOL in cancer patients. It includes the generic
CORE questionnaire - functional assessment of can-
cer therapy-general (FACT-G) - which contains gen-
eral questions divided into four primary QOL
domains (a total of 27 items): physical well-being
(PWB, 7 items, 0-28), social/family well-being (SWB,
7 items, 0-28), emotional well-being (EWB, 6 items,
0-24), and functional well-being (FWB, 7 items 0-
28), and an additional fatigue subscale (FS, 13 items,
0-52) directly related to the impact of fatigue on
daily activities. Three scores can be derived: a
FACIT-F trial outcome index (TOI) corresponding
to the sum of the PWB, FWB and FS subscales
(range from 0 to 108), a FACT-G total score corre-
sponding to the sum of the first four subscales
PWB, SWB, EWB, FWB (range from 0 to 108), a
FACIT-F total score corresponding to the sum of
t h eF A C T - Ga n dt h eF S( r a n g ef r o m0t o1 6 0 ) .
Higher scores are associated with higher QOL levels.
Statistical analysis
Data were expressed in mean and standard deviations (SD)
or median and ranges depending on the parametric or
non-parametric distribution of the variable. Mean compari-
sons of QOL scores between different sub-groups (gender,
age, educational level, marital status, children, occupational
status, tumour staging, 1-/2-stage thyroidectomy, initial
remnant ablation, depression) were performed using
Mann-Whitney tests or Student’s t-tests. Associations
between QOL scores and continuous variables (anxiety
level, interval surgery/
131I, baseline QOL) were analyzed
using Pearson’s correlation tests. Multivariate analyses
using multiple linear regression (forward-stepwise selec-
tion) were performed to determine variables potentially
linked to medium term QOL levels. The FACIT-F, the
FACIT-G, the FACIT-F TOI, and each of the five domains
were considered as separate dependent variables. The vari-
ables relevant to the models were selected from the uni-
variate FACIT-F total score analysis, based on a threshold
p-value ≤0.20 (gender, age group, marital status, depres-
sion, anxiety, and baseline QOL level). Initial remnant abla-
tion was included as an additional variable in the models
owing to its clinical interest. The final models incorporated
the standardized beta coefficients. The independent vari-
ables with the higher standardized beta coefficients are
those with a greater relative effect on QOL. The statistical
analyses were performed using the SPSS version 15.0 soft-
ware package (SPSS Inc., Chicago, IL, USA). All the tests
were two-sided. The statistical significance threshold was
defined as p < 0.05. To further explore the relation
between QOL levels (baseline and 9-month QOL) and the
previous selected variables (gender, age group, marital sta-
tus, depression, initial RAA, anxiety), a complementary
multiple correspondence analysis (MCA), allowing the
detection of clusters, was conducted using SPAD 3.21.
The MCA is a factor analysis approach. MCA may be
considered to be an extension of simple correspondence
analysis to more than two variables. MCA is used to pro-
duce a graphical representation of a set of categorical
variables, based on all possible pairs of cross tabulations.
MCA was performed projecting the variables onto a suc-
cession of two-dimensional planes. The relationship
between variables can be deduced from the relative posi-
tions of the modalities of the variables on the planes [23].
QOL and anxiety scores were arbitrarily categorised
using their median/25-75
th percentile values to define four
classes: 1-very low/2-low/3-high/4-very high QOL levels
or anxiety. All other variables were dichotomised in two
or more categories. Patient characteristics (illustrative vari-
ables) were projected on the plane in order to detect the
strength of the association with 9-month QOL, baseline
QOL, depression, and anxiety (active variables) [24].
Results
Patients characteristics
Eighty eight consecutive patients were enrolled of whom
83 patients were eligible for the final evaluation (2
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up, 2 with incomplete data). The socio-demographic,
clinical features and self-reported data are detailed in
Table 1. The mean age of the sample was 46.9 years
(SD 14.2), and the men:women ratio was 0.17. Approxi-
mately two thirds of patients declared having a partner,
had high school educational level or above, had at least
one child, and were in employment. According to our
inclusion criteria, most tumours were considered low-
risk for persistent disease. Thyroidectomy was per-
formed in one stage in more than 80% of cases. More
than 20% of the sample suffered from moderate or
severe depression at baseline. At the 9-month follow-up
control, only one patient had persistent disease.
Clinical and sociodemographic factors linked to QOL
Univariate analyses are detailed in Table 2. The 9-month
FACIT-F score was statistically linked to gender, age,
depression, anxiety, and baseline FACIT-F score. Older
patients reported significantly worse scores for the three
combined scores (FACIT-F, FACT-G, and FACIT-F
TOI), and for SWB, FWB, and FS dimensions. Men had
significantly better scores for two of the three scores
(FACIT-F and FACIT-F TOI), and for two dimensions
(PWB and FS). Depression and anxiety were always sig-
nificantly related to lower QOL (except depression and
the PWB dimension). All baseline QOL levels were posi-
tively correlated with 9-month QOL levels. None of the
scores and domains were linked with educational level,
marital status, occupational status or having children. A
trend towards higher QOL levels was observed in non-
working people, without children, with a partner and
with a higher educational level. Means scores did not
differ according to tumour staging (T or N) and thyroi-
dectomy stage (one- or two-stage). Interval surgery/131I
was also not correlated with 9-month QOL. Multivariate
models are detailed in Table 3. The selected variables
were gender, age group, marital status, initial RAA,
depression, anxiety, and baseline QOL level. No links
were found between the 9-month QOL and the modal-
ity of TSH stimulation. Marital status, baseline anxiety
and depression were not linked to QOL, except SWB
which was altered in subjects with initial depression.
Baseline QOL directly influenced the QOL at the fol-
low-up control. Older patients reported lower QoL
l e v e l si nt h e3s c o r e s ,a n d2o ft h e5d i m e n s i o n s( F W B
and FS). The PWB dimension was the single dimension
influenced by gender, indicating a lower score for
women. Figure 1 shows the results of the MCA regard-
ing the relationship between 9-month QOL and other
characteristics. Three clusters can be isolated in accor-
dance with the results of the linear regression. In the
right of the graph, a first cluster including ‘no depres-
sion’, ‘low anxiety levels’, and ‘high QOL levels’ (baseline
and 9-month) presented close similarities with ‘younger’,
‘men’, ‘partner’,a n d‘rhTSH’ response modalities. ‘Mild
depression’, ‘high anxiety’, ‘low baseline QOL’ are asso-
ciated with ‘low’ and ‘very low 9-month QOL’ and
represent a second cluster. ‘Single’ seems included in
this second cluster as ‘partner’ seems more closed of the
Table 1 Baseline characteristics of the sample (n = 83)
N (%)
M±S D
§
M [IQR]
§§
Age 46.91 ± 14.20
Gender Male 12 (14.5)
Female 71 (85.5)
Educational level Middle school 29 (34.9)
High school 54 (65.1)
Marital status Single 29 (34.9)
Partner 54 (65.1)
Children 0 18 (21.7)
> = 1 65 (78.3)
Occupational status Not working 35 (42.2)
Worker or student 48 (57.8)
Tumour T stage T1 37 (48.1)
T2 23 (29.9)
T3 17 (22.1)
Tumour N stage N0 28 (33.7)
N1 14 (16.9)
Nx 35 (42.2)
Thyroidectomy One-stage 65 (82.3)
Two-stage 14 (17.7)
Initial RAA Hypo 41 (49.4)
rhTSH 42 (50.6)
Interval surgery/
131I 41 [20-45]
Depression (BDI) No 47 (56.6)
Mild 18 (21.7)
Moderate 16 (19.3)
Severe 2 (2.4)
Anxiety level* STAI [20-80] 41.03 ± 10.53
QOL** FACIT-F [0-160] 118.63 ± 22.79
FACIT-G [0-108] 81.02 ± 14.13
FACIT-F TOI [0-108] 78.71 ± 18.42
PWB [0-28] 23.78 ± 4.14
SWB [0-28] 21.61 ± 5.08
EWB [0-24] 18.31 ± 3.76
FWB [0-28] 17.31 ± 5.90
FS [0-52] 37.61 ± 10.73
§M ± SD: mean ± standard deviation
§§M [IQR]: median [interquartile range]
*the higher the score, the higher anxiety level
**the higher the score, the higher the QOL level
PWB Physical wellbeing, SWB Social/family well-being, EWB Emotional well-
being, FWB Functional well-being, FS Fatigue
FACIT-G (PWB, SWB, EWB, and FWB subscales), FACIT-F (FACT-G, and FS
subscale), FACIT-F TOI (PWB, FWB, and FS subscales)
Taïeb et al. Health and Quality of Life Outcomes 2011, 9:33
http://www.hqlo.com/content/9/1/33
Page 3 of 7Table 2 Associations between 9-month FACIT scores/dimensions and sociodemographics, baseline clinical
characteristics
FACIT-F FACIT-G FACIT F TOI PWB SWB EWB FWB FS
[0-160] [0-108] [0-108] [0-28] [0-28] [0-24] [0-28] [0-52]
Gender*
Men 131.64 ± 15.91 87.14 ± 11.43 90.10 ± 10.95 25.00 ± 2.59 21.81 ± 5.52 19.75 ± 2.56 20.58 ± 3.96 44.50 ± 7.76
Women 118.10 ± 27.62 80.26 ± 16.54 78.34 ± 21.55 22.51 ± 5.26 21.14 ± 5.28 18.67 ± 4.14 17.94 ± 5.67 37.98 ± 11.76
p 0.026 0.172 0.008 0.017 0.690 0.396 0.126 0.070
Age group*
< 45 y 128.91 ± 17.70 86.29 ± 11.73 86.32 ± 14.50 23.79 ± 4.67 23.12 ± 3.58 19.34 ± 3.38 20.04 ± 4.72 42.39 ± 7.31
> = 45 y 113.86 ± 29.90 77.48 ± 17.73 75.68 ± 23.26 22.09 ± 5.34 19.88 ± 5.95 18.42 ± 4.36 17.09 ± 5.68 36.66 ± 13.16
p 0.009 0.012 0.020 0.164 0.005 0.338 0.023 0.020
Educational level*
Middle school 116.29 ± 24.85 79.57 ± 14.59 76.92 ± 19.80 22.29 ± 5.23 20.83 ± 4.77 18.70 ± 3.43 17.74 ± 4.97 37.12 ± 11.28
High school 122.21 ± 27.36 82.20 ± 16.75 81.82 ± 21.08 23.19 ± 4.92 21.45 ± 5.57 18.90 ± 4.22 18.65 ± 5.79 39.96 ± 11.51
p 0.358 0.492 0.328 0.455 0.625 0.832 0.488 0.305
Marital status*
Single 115.00 ± 28.40 78.70 ± 16.90 76.07 ± 22.25 22.52 ± 5.31 20.69 ± 5.04 18.24 ± 4.21 17.24 ± 5.89 36.31 ± 12.13
Partner 123.35 ± 25.10 82.82 ± 15.43 82.65 ± 19.45 23.10 ± 4.87 21.56 ± 5.44 19.18 ± 3.78 18.98 ± 5.22 40.63 ± 10.81
p 0.182 0.272 0.178 0.622 0.484 0.311 0.178 0.109
Number of children*
0 123.50 ± 25.83 83.67 ± 17.18 82.00 ± 19.27 23.39 ± 5.28 22.56 ± 4.33 18.94 ± 4.40 18.78 ± 5.67 39.83 ± 9.18
> = 1 119.20 ± 26.87 80.61 ± 15.72 79.61 ± 21.19 22.74 ± 4.97 20.85 ± 5.51 18.80 ± 3.84 18.21 ± 5.50 38.75 ± 12.11
p 0.551 0.479 0.670 0.631 0.232 0.895 0.705 0.727
Occupational status*
Not working 121.49 ± 24.53 81.62 ± 14.53 81.48 ± 19.41 23.19 ± 4.73 20.46 ± 5.83 19.55 ± 2.85 18.42 ± 5.14 39.87 ± 11.18
Worker or student 119.34 ± 28.01 80.93 ± 17.35 79.28 ± 21.62 22.59 ± 5.31 21.82 ± 4.98 18.24 ± 4.52 18.28 ± 5.90 38.41 ± 11.7
p 0.908 0.998 0.681 0.680 0.273 0.279 0.369 0.533
Initial remnant ablation*
Hypo# 119.22 ± 23.99 80.14 ± 14.01 79.84 ± 18.80 22.87 ± 4.78 21.01 ± 4.42 18.36 ± 3.69 17.90 ± 4.64 39.08 ± 10.78
rhTSH## 121.17 ± 29.06 82.44 ± 17.84 80.49 ± 22.56 22.90 ± 5.29 21.47 ± 6.06 19.30 ± 4.17 18.78 ± 6.26 38.92 ± 12.19
p 0.749 0.526 0.892 0.980 0.703 0.292 0.481 0.953
Depression*
No 130.25 ± 22.07 87.82 ± 13.36 87.00 ± 17.72 23.84 ± 4.49 23.57 ± 3.47 19.70 ± 3.75 20.72 ± 5.10 42.48 ± 9.88
Yes 108.16 ± 26.66 73.51 ± 15.55 71.97 ± 21.17 21.75 ± 5.42 18.46 ± 5.76 17.81 ± 3.97 15.50 ± 4.60 34.83 ± 11.92
p <0.001 <0.001 0.001 0.065 <0.001 0.033 <0.001 0.003
Anxiety level** -0.389 -0.408 -0.355 -0.250 -0.315 -0.326 -0.422 -0.326
p <0.001 <0.001 0.002 0.027 0.005 0.003 <0.001 0.004
Interval surgery/
131I** 0.005 0.010 -0.020 0.032 0.046 0.074 -0.098 -0.003
p 0.964 0.932 0.866 0.784 0.696 0.533 0.408 0.978
Baseline QOL** 0.574 0.618 0.531 0.385 0.601 0.483 0.630 0.473
p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
#Hypo:
131I during hypothyroidism, ##rhTSH:
131I after rhTSH injections
PWB Physical well-being, SWB Social/family well-being, EWB Emotional well-being, FWB Functional well-being, FS Fatigue
FACIT-G (PWB, SWB, EWB, and FWB subscales), FACIT-F (FACT-G, and FS subscale), FACIT-F TOI (PWB, FWB, and FS subscales) the higher the score, the higher the
QOL level
* mean ± standard deviation, p: p-value Student’s t-test or Mann-Whitney test
** Pearson’s correlation coefficient, p: p-value Pearson’s test
Bold values: p < 0.05
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Page 4 of 7Table 3 Factors linked to the 9-month FACIT scores/dimensions: multivariate analysis (standardized beta coefficient)
FACIT-F FACIT-G FACIT-F TOI PWB SWB EWB FWB FS
Gender (0 men, 1 women) ß -0.164 -0.128 -0.177 -0.230 0.050 -0.171 -0.097 -0.176
p 0.112 0.187 0.098 0.043 0.572 0.125 0.321 0.111
Age group (0 <45 y, 1 ≥ 45 y) ß -0.223 -0.197 -0.236 -0.179 -0.163 -0.090 -0.202 -0.248
p 0.038 0.050 0.033 0.119 0.076 0.413 0.043 0.031
Marital status (0 single, 1 partner) ß 0.051 0.021 0.047 -0.010 0.017 0.059 0.040 0.089
p 0.636 0.839 0.678 0.932 0.857 0.607 0.692 0.447
Depression (0 no, 1 yes) ß -0.026 -0.056 0.036 0.116 -0.441 0.199 -0.118 0.003
p 0.838 0.698 0.818 0.471 0.001 0.213 0.409 0.984
Initial therapy (0 hypo, 1 rhTSH) ß -0.056 -0.029 -0.064 -0.041 -0.010 0.001 0.004 -0.070
p 0.595 0.767 0.555 0.715 0.908 0.997 0.970 0.532
Anxiety level* ß -0.076 -0.061 -0.079 -0.165 0.128 -0.172 -0.076 -0.076
p 0.588 0.649 0.587 0.284 0.285 0.258 0.565 0.616
Baseline QOL** ß 0.444 0.499 0.442 0.380 0.513 0.500 0.447 0.357
p 0.002 <0.001 0.003 0.004 <0.001 0.001 <0.001 0.012
PWB Physical well-being, SWB Social/family well-being, EWB Emotional well-being, FWB Functional well-being, FS Fatigue
FACIT-G (PWB, SWB, EWB, and FWB subscales), FACIT-F (FACT-G, and FS subscale), FACIT-F TOI (PWB, FWB, and FS subscales)
ß: standardized beta coefficient (ß represents the change in standard deviation units in QOL score resulting from a change of one standard deviation in the
different independent variables);
p: p-value
*the higher the score, the higher anxiety level
**the higher the score, the higher the QOL level
Bold values: p < 0.05
Figure 1 Multiple correspondence analysis (MCA), plane of the first two factorial axes (factor 1 and factor 2) representing relationship
with the 9-month QOL Green circles: 9-month QOL (very low/low/high/very high); Black circles: anxiety (very low/low/high/very high),
depression (no/mild/moderate/severe), baseline QOL (very low/low/high/very high); Pink circles: patients’ parameters; single/partner, <45y/> =
45y, men/women, hypo/rhTSH.
Taïeb et al. Health and Quality of Life Outcomes 2011, 9:33
http://www.hqlo.com/content/9/1/33
Page 5 of 7first one, but ‘age group’ is probably a confounding fac-
tor as demonstrated by the linear regression. A third
cluster groups together ‘moderate depression’, ‘severe
depression’, ‘very high anxiety level’,a n d‘very low base-
line QOL’.
Discussion
In recent years, attention has been paid to the effect of
treatment on QOL in cancer patients [25].
We have previously found as Pacini et al, that the use
of rhTSH preserves the QOL of patients in the peri-
ablation period [7,8]. To our knowledge, this is the first
longitudinal study which assesses the determinant fac-
tors of QOL at the first post-ablation follow-up control
and seems show that QOL at the first post-ablation fol-
low-up (the overall 9-month QOL scores: FACIT-F,
FACT-G, FACIT-F TOI) is not affected by modality of
TSH stimulation prior to therapy and influenced only
by patient age and the baseline QOL. Due to the lack of
evaluation of baseline status, other QOL studies have
not accounted for the potential impact of baseline QOL.
In the present study, numerous confounding factors
have been incorporated including socio-demographic
parameters (age, gender, educational level, marital sta-
tus, having children, occupational status), initial clinical
characteristics (tumour staging, RAA therapy, surgery/
131I time), and psychological variables (anxiety, depres-
sion) that aid in a more reliable assessment. Age at
initial treatment is often quoted as a QOL predictive
factor with older patients more vulnerable than the
young [9,12-14]. As in other studies, gender and marital
status [12,13] and educational level did not influence
QOL [13]. In our study tumour stage and the thyroi-
dectomy dynamic (one- or two-stage) also did not influ-
ence QOL outcome. However this conclusion should be
qualified by the fact that our study cohort consisted of
low-risk patients given that only one patient had persis-
tent disease at 9 months and the two other patients
with persistent metastatic lymph nodes underwent sur-
gery during the first 6 months following ablation and
were excluded from the analysis. Our results failed to
demonstrate any influence of depression and anxiety on
median-term QOL, domains often defined as indepen-
dent parameters linked to QOL [13]. These last two fac-
tors may be of significant clinical value for health care
workers. Despite these interesting findings, our study
suffers from several limitations. The sample size was lar-
ger than the referenced prospective study [7] but too
small to be compared to some cross-sectional studies
[12,13]. In our multivariate analysis, several determi-
nants might have been missed by the low statistical
power and other studies with larger populations will be
necessary. But this nevertheless represents an improve-
ment on studies that do not take into account the
potential QOL confounding factors [7,10,16]. The repre-
sentativeness of our cohort may be questioned since it
differs from the Pacini study which whilst using the
same design comprised more male patients (20% versus
14.5%), and a lower mean age (43 versus 47 years). The
comparison with cross-sectional studies is difficult
because parameters have been collected at the time of
the study and not at the time of the initial treatment
resulting in a slightly older cohort than in our study
[10,12,16]. Also our proportion of pT1 was higher than
in Pacini’s study, and we did not include pT1 stage and/
or M1 disease. It is clear that there are multiple strate-
gies for assessing QOL, using specific or generic ques-
tionnaires but it seems appropriate to adopt a cancer-
specific instrument which is more sensitive for detecting
and quantifying small changes [26]. Patients with low
baseline QOL scores should be specificaly offered addi-
tional clinical support: cancer support groups for
patients and families, more targeted cancer-related
patient information, nurse and pyschologist’s aides, par-
ticipation in treatment decision-making.
Conclusions
Medium- term QOL outcomes in thyroid cancer
patients are mainly determined by pre-ablation QOL
and seem unaffected by the modality of stimulation
adopted. The assessment of baseline QOL may be a use-
ful tool in order to target patients at risk of poor subjec-
tive outcomes.
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